TCRαβ-depleted haploidentical donor hematopoietic cell transplantation with memory T-cell DLI and blinatumomab

This specialized cell therapy protocol, developed by St. Jude Children's Research Hospital, is an advanced hematopoietic cell transplantation (HCT) strategy for pediatric and young adult patients with high-risk hematologic malignancies. The procedure involves the use of a haploidentical donor graft that has been selectively depleted of TCRαβ+ T cells and CD19+ B cells using the CliniMACS device. This selective depletion is intended to prevent graft-versus-host disease (GVHD) while retaining TCRγδ+ T cells and natural killer (NK) cells, which provide essential anti-leukemic and anti-viral activity. Following the initial transplant, patients receive an infusion of CD45RA-depleted (memory) T cells to further enhance immune reconstitution without increasing the risk of GVHD. For patients with CD19+ malignancies, the protocol also incorporates the prophylactic use of blinatumomab, a bispecific T-cell engager, to target and eliminate residual disease and reduce the risk of relapse.

Other names

TCRα/β+-St. Jude Children's Research Hospital-acute lymphoblastic leukemia-acute myeloid leukemia-myelodysplastic syndromes-NK-cell leukemia-Hodgkin lymphoma-non-Hodgkin lymphoma-juvenile myelomonocytic leukemia-chronic myeloid leukemiaTCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLITCRαβ-depleted haploidentical donor HCTTCRαβ/CD19-depleted donor graftsCD45RA-depleted memory T-cell DLICD-45RA-depleted memory T-cell DLICD 45RA-depleted memory T-cell DLI